HB1396, the PILLS Act, would amend the Internal Revenue Code to create two new federal tax incentives aimed at expanding domestic production of generic drugs and biosimilars. The first is a production credit for eligible components produced in the United States and sold to unrelated persons, with a base credit generally equal to 30% of value added and 35% for final production of drug substances, drug products, and biological products. The credit also includes a domestic content bonus and phases down for sales after 2030, ending after 2033. The bill excludes taxpayers that are foreign entities of concern and bars credit eligibility for components produced at certain FDA-warning-letter facilities or facilities already benefiting from a related investment credit.
The second major provision creates a 25% investment tax credit for qualified facilities used to produce eligible components, including buildings and structural components used in production, but not office or administrative space. This credit applies to property placed in service after December 31, 2026, and terminates for property whose construction begins after December 31, 2028. The bill also allows both credits to be claimed through elective payment in certain cases and to be transferred under existing tax credit transfer rules.
In practical terms, the bill would add new sections 45BB and 48F to the tax code and make conforming changes to the general business credit, elective payment, and transferability provisions. It would affect pharmaceutical manufacturers, biosimilar producers, suppliers of drug inputs, and investors in domestic manufacturing facilities, while also giving the Treasury Department authority to issue implementing regulations and guidance. The stated policy goal is to encourage long-term U.S.-based production of lifesaving medicines and reduce reliance on foreign supply chains.
The available legislative history shows no recorded committee debate or votes, so there is no documented floor or committee sentiment to assess. Based on the bill text alone, the measure appears designed as a pro-manufacturing, supply-chain resilience, and domestic-content incentive, with built-in restrictions reflecting national security and quality-control concerns. Because there is no transcript or vote data, there is no clear evidence of support or opposition from specific lawmakers or stakeholder groups in the provided record.
Notable points of potential contention include the cost of the new tax credits, the use of federal tax policy to favor specific industries, and the exclusion of foreign entities of concern, which may be viewed as both a security safeguard and a trade restriction. The FDA warning-letter exclusion and the interaction with other credits could also raise implementation questions for manufacturers. The domestic content bonus and phaseout schedule may be debated by supporters and critics over whether they are sufficient to meaningfully expand U.S. production without creating overly complex compliance burdens.
The bill would amend the Internal Revenue Code by adding new sections 45BB and 48F to create a production tax credit and an investment tax credit for generic drugs and biosimilars. It would also modify the general business credit, elective payment rules, and credit transfer provisions so these new credits can be claimed, monetized, or transferred under existing tax mechanisms. The measure would primarily affect pharmaceutical manufacturers, biosimilar producers, suppliers of drug inputs and materials, and owners of domestic production facilities, while excluding foreign entities of concern and certain facilities with unresolved FDA warning letters.
No committee transcript or vote record is available, so there is no documented legislative sentiment from debate or roll call. The bill’s structure suggests a generally supportive policy approach toward domestic pharmaceutical manufacturing, supply-chain resilience, and U.S. production of essential medicines. At the same time, the absence of recorded discussion means there is no direct evidence of bipartisan support, opposition, or negotiated amendments in the provided materials.
Potential points of contention include the fiscal cost of the credits, whether targeted tax incentives are the best way to strengthen drug supply chains, and how broadly the domestic-content bonus should apply. The exclusion of foreign entities of concern may be supported on national-security grounds but criticized as restrictive or trade-sensitive. Manufacturers may also dispute the compliance burden created by documentation rules, FDA warning-letter exclusions, and the interaction with other federal tax credits.